A better delivery system brings anti-inflammatory therapies to critical sites
Arthritis flares — the unpredictable and often sudden worsening of arthritis symptoms — can be debilitating. These episodes can make the management of inflammatory arthritis, which includes rheumatoid arthritis and psoriatic arthritis, challenging for patients and physicians.
But investigators at Harvard-affiliated Brigham and Women’s Hospital (BWH) have found that flares may also represent an important opportunity for improving treatment options.
In experiments carried out in the lab, BWH bioengineers have developed a hydrogel — a soft, flexible material that can be loaded with arthritis drugs and injected locally into an inflamed joint. Instead of delivering the drug continuously at a steady rate, the hydrogel is designed to respond to increased disease activity during flares, releasing the drug when symptoms worsen. The team’s laboratory-based findings are published this week in Nature Communications and investigators are working on next steps to bring their technology closer to the clinic.
“Arthritis represents a huge unmet clinical need,” said co-senior author Jeff Karp,a bioengineer and principal investigator at BWH and Harvard Medical School (HMS) professor of medicine. “Although new therapeutics have been developed, many have had systemic, toxic effects. We wanted to design a delivery system that could be efficient, deliver drugs locally, and release drugs in response to inflammation.”
The newly created flare-responsive hydrogel is made from triglycerol monostearate (TG-18), a compound from the Food and Drug Administration’s list of “generally recognized as safe” compounds. TG-18 is a molecule capable of self-assembling, meaning that it can form a gel-like structure comprising fibers. This structure can be easily injected as a suspension. In this study, the TG-18 hydrogel was loaded with triamcinolone acetonide (TA), used here as a model drug, but could potentially be loaded with many other kinds of anti-inflammatory compounds.
“The hydrogel is designed so that drug release is triggered by the activity of specific, arthritis-related enzymes that are increased during flares. To test the TG-18 hydrogel, we exposed the gel to several different kinds of environments mimicking conditions in arthritic joints,” said Nitin Joshi, co-first author on the work and an instructor of medicine at BWH and HMS.
When the gel was incubated in synovial fluid from a healthy human joint, drug release was minimal, but when incubated in synovial fluid from a patient with rheumatoid arthritis, the drug was readily released from the hydrogel. Importantly, the drug supply was not exhausted in one spike of synovial fluid — instead, it could be released in response to multiple spikes over time. The team also tested the hydrogel’s effects on cells from cartilage and joints, and found that it appeared to be safe.
The team further tested the clinical efficacy of the TG-18 hydrogel in a mouse model of inflammatory arthritis. They chose the K/BxN serum transfer model, in which disease severity can be precisely controlled, which allowed them to test the hydrogel in animals with different degrees of arthritis severity. They found that when arthritis was more severe, the locally injected hydrogel degraded more rapidly, corresponding to increased drug release. Swelling and severity of arthritis diminished in response to the drug-loaded hydrogel.
One of the advantages of the hydrogel is that it offers the promise of treating arthritis specifically in the joints where the disease is flaring, rather than delivering a drug throughout the body.
“Local therapy could be a viable treatment option for patients with only one or a few inflamed joints, said co-corresponding author Joerg Ermann, a rheumatologist in the BWH Division of Rheumatology, Immunology, and Allergy and HMS instructor in medicine. “Moreover, if a patient is already on a systemic drug but is experiencing a flare in a limited number of joints, we could specifically treat these joints rather than switching to systemic therapy or adding another systemic drug. Having this option would substantially increase our ability to successfully manage arthritis flares in the clinic.”
The team will continue testing the hydrogel in preclinical models to further validate it, and continue to advance toward human clinical trials. The technology has been licensed by Alivio Therapeutics, which is developing therapies to treat inflammatory disorders via targeted disease immunomodulation.
Learn more: Treating inflammatory arthritis with hydrogel
The Latest on: Inflammatory arthritis
via Google News
The Latest on: Inflammatory arthritis
- Environmental Nutrition: Foods and inflammation: Cooling the fire within on February 19, 2019 at 2:32 pm
and may in turn help reduce the risk and symptoms of a variety of disorders influenced by inflammation including heart attack, stroke, several forms of cancer and autoimmune diseases such as rheumatoi... […]
- Inflammation: Study explains loss of protective abilities of T cells on February 19, 2019 at 6:55 am
In autoimmune diseases such as arthritis or multiple sclerosis (MS) the body attacks its own tissue, causing inflammation of the nervous system or the joints, for example. A special group of immune ce... […]
- Canine Arthritis Treatment Market Size to Grow by 2028 with Top Players are Zoetis Inc., Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc. on February 19, 2019 at 6:37 am
Based on the treatment type, the Canine Arthritis Treatment is segmented into non-steroidal anti-inflammatory drugs, opioids and stem cell therapy. The non-steroidal anti-inflammatory drugs is expecte... […]
- Canine Arthritis Treatment Market is Expected to Get US$ 3.00 Billion by 2024 on February 18, 2019 at 8:30 am
Based on Treatment Type it covers Non-steroidal anti-inflammatory drugs, Opioids and Stem Cell Therapy. Based on route of administration it covers Oral and Injectable. The Canine Arthritis Treatment M... […]
- Tumour Necrosis Factor-α Inhibition Improves Stroke Outcome in a Mouse Model of Rheumatoid Arthritis on February 18, 2019 at 2:49 am
Rheumatoid Arthritis (RA) is a chronic inflammatory disorder where incidence and severity of myocardial infarction are increased. Data on the incidence and outcome of stroke are conflicting. Thus, we ... […]
- Expert lays out mystery of why some gout is non-inflammatory on February 16, 2019 at 12:45 pm
noting the factors that lead to inflammation are genetics, environment and sex predisposition. Gouty arthritis pathogenesis for genetics is URAT-1, “the environment is alcohol” and there are more men ... […]
- Does Eating Gin-Soaked Raisins Help Relieve Arthritis Pain? on February 16, 2019 at 9:37 am
Arthritis is an auto-immune disease that causes those afflicted with it to suffer loss of mobility and copious amounts of pain. While drug therapies are available to help alleviate some of the sufferi... […]
- Curcumin’s Anti-inflammatory Activity Could Fight Arthritis Pain on February 15, 2019 at 6:59 am
Curcumin’s anti-inflammatory activity could fight arthritis pain. It is worth mentioning that there are quite a number of studies about curcumin’s pain-relieving action. This phytochemical ... […]
- Study: Cranberry Juice May Decrease Inflammation in Women with Rheumatoid Arthritis on February 14, 2019 at 12:59 pm
Paraná, Brazil—A study conducted on the effects of cranberry juice in women with rheumatoid arthritis (RA) provides evidence that cranberry juice can be beneficial for decreasing the disease activity ... […]
via Bing News